Bernd Disse
Boehringer Ingelheim
79 Papers
569 Citations
Bernd Disse is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: COPD & Respimat. The author has an hindex of 20, co-authored 77 publications.
Chat about Author
Papers
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
Luca Richeldi,Roland M. du Bois,Ganesh Raghu,Arata Azuma,Kevin K. Brown,Ulrich Costabel,Vincent Cottin,Kevin R. Flaherty,David M. Hansell,Yoshikazu Inoue,Dong Soon Kim,Martin Kolb,Andrew G. Nicholson,Paul W. Noble,Moisés Selman,Hiroyuki Taniguchi,Michèle Brun,Florence Le Maulf,Mannaig Girard,Susanne Stowasser,Rozsa Schlenker-Herceg,Bernd Disse,Harold R. Collard +22 more
TL;DR: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintinganib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients.
Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD
Helgo Magnussen,Bernd Disse,Roberto Rodriguez-Roisin,Anne Kirsten,Henrik Watz,Kay Tetzlaff,Lesley Towse,Helen Finnigan,Ronald Dahl,Marc Decramer,Pascal Chanez +10 more
TL;DR: In patients with severe COPD receiving tiotropium plus salmeterol, the risk of moderate or severe exacerbations was similar among those who discontinued inhaled glucocorticoids and those who continued glucocORTicoid therapy, but there was a greater decrease in lung function during the final step of glucoc Corticoid withdrawal.
Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial
Huib A. M. Kerstjens,Bernd Disse,Winfried Schröder-Babo,Theo A. Bantje,Martina Gahlemann,Ralf Sigmund,Michael Engel,Jan A. van Noord +7 more
TL;DR: The addition of once-daily tiotropium to asthma treatment, including a high-dose inhaled corticosteroid plus a long-acting β₂-agonist, significantly improves lung function over 24 hours in patients with inadequately controlled, severe, persistent asthma.
276
Ba 679 BR, a novel long-acting anticholinergic bronchodilator
TL;DR: Ba 679 represents a novel type of antimuscarinic bronchodilator with a long duration of action, most likely due to its slow dissociation from Hm3-receptors.
164